» Articles » PMID: 20371665

6-18F-fluoro-L-dihydroxyphenylalanine Positron Emission Tomography is Superior to 123I-metaiodobenzyl-guanidine Scintigraphy in the Detection of Extraadrenal and Hereditary Pheochromocytomas and Paragangliomas: Correlation with Vesicular Monoamine...

Overview
Specialty Endocrinology
Date 2010 Apr 8
PMID 20371665
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Pheochromocytomas (PHEOs) and paragangliomas (PGLs) may be better detected by (18)F-fluorodihydroxyphenylalanine-positron emission tomography (FDOPA-PET) than (123)I-metaiodobenzyl-guanidine (123-I-MIBG) scintigraphy.

Objective: The objective of the study was to correlate functional imaging results with immunohistochemical, molecular-genetic, and biochemical findings.

Design And Setting: Thirty consecutive patients with suspected PHEO/PGL presenting at a tertiary referral centre were investigated in a prospective study.

Patients: Twenty-five patients had confirmed PHEO/PGL. Thirteen of 25 patients had a hereditary PHEO/PGL syndrome (two multiple endocrine neoplasia II, six succinate dehydrogenase complex, subunit D, two succinate dehydrogenase complex, subunit B, one von Hippel Lindau tumor suppressor protein, two Neurofibromatosis-1), and 12 of 25 were classified as sporadic. Five patients had hormonally inactive adrenal incidentalomas.

Main Outcome Measures: In all patients computed tomography scan and/or magnetic resonance imaging as well as both 123-I-MIBG scintigraphy and FDOPA-PET were performed. Resected tumors were examined by immunohistochemistry for expression of the vesicular monoamine transporter (VMAT)-1 and -2 and other markers.

Results: A total of 64 lesions were found with both functional imaging modalities. FDOPA-PET detected 62 lesions, whereas only 34 lesions were detected by 123-I-MIBG scintigraphy. This resulted in an overall sensitivity and specificity for FDOPA-PET of 98 and 100% and for MIBG of 53 and 91%, respectively. Comparable sensitivities were found for adrenal and extraadrenal abdominal lesions (94 vs. 97%), whereas in thoracic/cervical lesions, the sensitivity for 123-I-MIBG scintigraphy (15%) was inferior to that of FDOPA-PET imaging (100%). Immunohistochemistry demonstrated a lack of VMAT-1 expression in all MIBG-negative tumors. Clinical predictors for MIBG negativity were a predominant norepinephrine/normetanephrine secretion, an age less than 45 yr, and a hereditary cause.

Conclusion: FDOPA-PET is superior to 123-I-MIBG scintigraphy in patients with extraadrenal, predominantly noradrenaline-secreting, and hereditary types of PHEO/PGL. The lack of VMAT-1 expression predicts negativity for MIBG-scintigraphy.

Citing Articles

Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles.

Flynn A, Pattison A, Balachander S, Boehm E, Bowen B, Dwight T Res Sq. 2024; .

PMID: 38978571 PMC: 11230496. DOI: 10.21203/rs.3.rs-4410500/v1.


Pheochromocytoma With High Adrenocorticotropic Hormone Production Capacity Without Pigmentation and Cushingoid Symptoms: A Case Report With a Literature Review.

Mizutani G, Isshiki M, Shimizu E, Saito D, Shimada A Cureus. 2024; 16(2):e53358.

PMID: 38435205 PMC: 10907887. DOI: 10.7759/cureus.53358.


Effectiveness of F-FDG PET/CT in finding lung metastasis from a retroperitoneal paraganglioma.

Chikasue T, Kurata S, Nagata S, Tanoue S, Sumi A, Gobaru M Asia Ocean J Nucl Med Biol. 2024; 12(1):46-51.

PMID: 38164231 PMC: 10757060. DOI: 10.22038/AOJNMB.2023.74066.1516.


A Prospective Comparative Study of 18 F-FDOPA PET/CT Versus 123 I-MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma.

Sung C, Lee H, Lee D, Kim Y, Kim J, Lee S Clin Nucl Med. 2023; 49(1):27-36.

PMID: 38054497 PMC: 11805481. DOI: 10.1097/RLU.0000000000004963.


Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas.

Gabiache G, Zadro C, Rozenblum L, Vezzosi D, Mouly C, Thoulouzan M Cancers (Basel). 2023; 15(18).

PMID: 37760633 PMC: 10526298. DOI: 10.3390/cancers15184666.